Fructose-1,6-bisphosphate inhibits the expression of inducible nitric oxide synthase caused by oxygen-glucose deprivation through the inhibition of glutamate release in rat forebrain slices
被引:18
作者:
Cárdenas, A
论文数: 0引用数: 0
h-index: 0
机构:UCM, Fac Med, Dept Farmacol, Madrid 28040, Spain
Cárdenas, A
Hurtado, O
论文数: 0引用数: 0
h-index: 0
机构:UCM, Fac Med, Dept Farmacol, Madrid 28040, Spain
Hurtado, O
Leza, JC
论文数: 0引用数: 0
h-index: 0
机构:UCM, Fac Med, Dept Farmacol, Madrid 28040, Spain
Leza, JC
Lorenzo, P
论文数: 0引用数: 0
h-index: 0
机构:UCM, Fac Med, Dept Farmacol, Madrid 28040, Spain
Lorenzo, P
Bartrons, R
论文数: 0引用数: 0
h-index: 0
机构:UCM, Fac Med, Dept Farmacol, Madrid 28040, Spain
Bartrons, R
Lizasoain, I
论文数: 0引用数: 0
h-index: 0
机构:UCM, Fac Med, Dept Farmacol, Madrid 28040, Spain
Lizasoain, I
Moro, MA
论文数: 0引用数: 0
h-index: 0
机构:
UCM, Fac Med, Dept Farmacol, Madrid 28040, SpainUCM, Fac Med, Dept Farmacol, Madrid 28040, Spain
Moro, MA
[1
]
机构:
[1] UCM, Fac Med, Dept Farmacol, Madrid 28040, Spain
[2] Unitat Bioquim & Biol Mol, Barcelona 08907, Spain
ATP levels;
glutamate;
neuroprotective;
nitric oxide;
oxygen-glucose deprivation;
D O I:
10.1007/s002100000286
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Fructose-1,6-bisphosphate (FBP) is a glycolytic pathway intermediate with a neuroprotective action in animal models of brain ischaemia. We addressed the question of whether FBP acts through inhibiting inducible nitric oxide synthase (iNOS) expression via reduction of glutamate release, since we have recently demonstrated that glutamate is involved in the expression of iNOS. FBP (5 mM) added to the incubation solution of rat forebrain slices subjected to oxygen-glucose deprivation (OGD) inhibited glutamate release significantly (around 40%). FBP also inhibited the induction of the calcium-independent NOS activity and reduced the levels of iNOS protein in rat forebrain slices subjected to OGD. We conclude that the action of FBP by reducing glutamate release and iNOS expression, both of which have been implicated in cell damage, is a reason for further evaluation of FBP as a neuroprotectant.